Gut microbiome-associated predictors as biomarkers of response to advanced therapies in inflammatory bowel disease: a systematic reviewSusanna Meade, Genelle Lunken, Elizabeth Squirell et al.|Gut Microbes|2023Cited by 48
Real-world experience and long-term outcomes of a mandatory non-medical switch of adalimumab originator to biosimilars in inflammatory bowel diseaseJeremy Liu Chen Kiow, Greg Rosenfeld, Thomas Hoang et al.|World Journal of Gastroenterology|2024Cited by 9